GLOSSARY ENTRY (DERIVED FROM QUESTION BELOW) | ||||||
---|---|---|---|---|---|---|
|
16:17 Feb 8, 2020 |
French to English translations [PRO] Medical - Medical (general) / Bone marrow biopsy | |||||||
---|---|---|---|---|---|---|---|
|
| ||||||
| Selected response from: Anne Schulz Germany Local time: 02:25 | ||||||
Grading comment
|
Summary of answers provided | ||||
---|---|---|---|---|
4 | update on CLL/lymphoma |
| ||
4 | Review on .... |
| ||
3 | CLL/lymphoma characterization, DD CLL/lymphoma |
|
Discussion entries: 3 | |
---|---|
update on CLL/lymphoma Explanation: ymphoma.org › aboutlymphoma › cll › cllfdaupd... Chronic Lymphocytic Leukemia: FDA Updates - Lymphoma ... Traduire cette page Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: FDA Updates. ... September 24, 2018 – The U.S. Food and Drug Administration (FDA) approved duvelisib (COPIKTRA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. |
| |
Login to enter a peer comment (or grade) |
Review on .... Explanation: .. |
| |
Login to enter a peer comment (or grade) |
CLL/lymphoma characterization, DD CLL/lymphoma Explanation: CD5 and CD19 (among others) help to distinguish CLL from other lymphoma diseases with similar clinical features; therefore narrowing down the diagnosis, or "differential diagnosis" is probably one aspect of "mise au point". CD38 is a prognostic parameter for CLL; therefore "characterization" of CLL may be another aspect. "Focusing on CLL/lymphoma", "Pinpointing",... some English native may probably come up with a better non-technical rendering of "Mise au point". -------------------------------------------------- Note added at 1 day 21 hrs (2020-02-10 13:46:14 GMT) -------------------------------------------------- In the ProZ.com reference liz askew posted in the discussion box, "workup" or "assessment" were also proposed and might be suitable for a table heading. |
| |
Grading comment
| ||
Login to enter a peer comment (or grade) |
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.